Angiogenic markers: molecular targets for personalized medicine in pituitary adenoma

Personalized Medicine
Cristiana TanaseDorel Arsene

Abstract

Pituitary adenomas are typically slow-growing and histologically benign tumors that can occasionally behave in a malignant-like manner, invading adjacent structures or recurring after treatment. Using protein analysis methods and multiplex xMAP assays, we aimed to find out if these particular types of tumors express angiogenic markers VEGF and basic FGF (bFGF), which are associated with tumor growth and invasiveness, and quantify them in order to establish their usefulness as biomarkers. We have analysed the expression of angiogenic markers VEGF and bFGF in serum and tissue specimens from 66 pituitary adenomas (43 invasive and 23 noninvasive). For serum analysis, we used xMAP and ELISA, and for tissue analysis, we performed histopathology and immunohistochemistry. We measured the serum angiogenic factors in pituitary adenomas. The quantification methods revealed significant differences between pituitary adenoma patients and controls, for both VEGF (212.4 vs 112.5 pg/ml in controls) and bFGF (mean value of 12.6 vs 10.8 pg/ml in controls), and also differentiated between invasive and noninvasive adenomas (p < 0.05). The tissue expression of VEGF and bFGF strongly correlated with their serum level increase. Our findings can be fur...Continue Reading

References

Sep 13, 2000·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·Y NagaiK Kobayashi
Mar 19, 2002·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Sergio VidalKalman Kovacs
Sep 6, 2002·The Journal of Clinical Endocrinology and Metabolism·C J McCabeN J L Gittoes
Jan 23, 2003·Microscopy Research and Technique·Johbu ItohRobert Yoshiyuki Osamura
May 24, 2003·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Shinji FukuiHidetoshi Ooigawa
Oct 23, 2003·Endocrine Reviews·Helen E TurnerJohn A H Wass
Jul 30, 2004·Frontiers of Hormone Research·N Garcia de la TorreH E Turner
Oct 18, 2005·Human Pathology·María NiveiroAntonio Picó
Jan 18, 2006·Pituitary·Antonio CiccarelliAlbert Beckers
May 9, 2008·The New England Journal of Medicine·Robert S Kerbel
Jul 31, 2008·Molecular & Cellular Proteomics : MCP·John M KoomenWilliam S Dalton
May 14, 2009·Seminars in Ophthalmology·Adam B Cohen, Simmons Lessell
Nov 10, 2009·Expert Review of Molecular Diagnostics·Cristiana Pistol TanaseRadu Albulescu
May 18, 2010·Endocrine Pathology·Carolina CristinaDamasia Becu-Villalobos
Nov 26, 2010·Neurosurgery·Fateme SalehiMichael Cusimano
Mar 17, 2011·The Journal of Pharmacology and Experimental Therapeutics·Guillermina María LuqueDamasia Becu-Villalobos
Jul 5, 2011·Hormones : International Journal of Endocrinology and Metabolism·Olga MoshkinKalman Kovacs
Dec 29, 2011·Journal of Nucleic Acids·Klaus HolzmannBrigitte Marian
Feb 23, 2012·Brain Pathology·Aurélie CorneliusClaude-Alain Maurage
Mar 1, 2012·BMC Bioinformatics·Alejandra González-BeltránAnthony Finkelstein
Dec 12, 2012·Clinical Biochemistry·Rachel A CravenRosamonde E Banks
Jan 3, 2013·International Journal of Cancer. Journal International Du Cancer·Neill PataniMitch Dowsett
Jan 18, 2013·International Journal of Nanomedicine·Farooq A Shiekh

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
surgical resection

Software Mentioned

STarStation
SPSS

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.